Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts give Replimune an average rating of Hold from 10 analysts (2 sell, 2 hold, 6 buy), with a mean 12‑month price target of $10.00.
• Sentiment is mixed: Piper Sandler raised its target to $14 (overweight) and Wedbush to $19 (outperform), while Weiss Ratings reissued a sell.
• Shares trade around $7.54 (market cap ≈ $622.6M); the company is loss‑making but beat last quarter’s EPS (-$0.77 vs. -$0.85 estimate), and analysts forecast about -2.97 EPS for the current year.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $10.00.

Several equities analysts recently commented on REPL shares. Piper Sandler upped their price target on shares of Replimune Group from $13.00 to $14.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, Wedbush boosted their target price on Replimune Group from $18.00 to $19.00 and gave the company an "outperform" rating in a research report on Wednesday, February 4th.

Replimune Group Price Performance

NASDAQ:REPL opened at $7.54 on Friday. The firm has a market capitalization of $622.60 million, a price-to-earnings ratio of -2.19 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The business has a 50 day simple moving average of $7.54 and a 200-day simple moving average of $7.74. Replimune Group has a 1 year low of $2.68 and a 1 year high of $13.24.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.08. Equities analysts forecast that Replimune Group will post -2.97 EPS for the current year.

Hedge Funds Weigh In On Replimune Group

Large investors have recently bought and sold shares of the business. International Assets Investment Management LLC bought a new position in Replimune Group in the 4th quarter valued at $29,000. Russell Investments Group Ltd. lifted its position in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock worth $33,000 after purchasing an additional 7,569 shares during the last quarter. CWM LLC lifted its position in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company's stock worth $39,000 after purchasing an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company's stock valued at $58,000 after purchasing an additional 6,873 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter worth about $69,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.